Cost-Effectiveness Analysis of Antihypertensive Therapy  in Outpatient Hypertension Patients  at Hospital X in Wajo Regency

Alya  Rahmah Safitri; Ismail  Ibrahim; Ida  Adhayanti

doi:10.18502/jppm.v9i3.14192

Alya Rahmah Safitri Department of Pharmacology, Poltekkes Kemenkes Makassar, Bengaluru, Karnataka, India
Ismail Ibrahim Department of Pharmacology, Poltekkes Kemenkes Makassar, Bengaluru, Karnataka, India.
Ida Adhayanti Assistant Professor, Department of Pharmacology, Poltekkes Kemenkes Makassar, Bengaluru, Karnataka, India.

DOI: https://doi.org/10.18502/jppm.v9i3.14192

Keywords: Hypertension, Pharmacoeconomics, Cost-Effectiveness Analysis

Abstract

Background: Hypertension is a chronic disease that cannot be cured and can only be controlled but requires long-term treatment, even for life. The variety of antihypertensive treatments makes it necessary to adjust the choice of treatment not only in terms of effectiveness, but also in terms of cost. Therefore, a pharmacoeconomic approach is needed, namely Cost Effectiveness Analysis (CEA) to compare the effectiveness of therapy and costs of several alternative therapies used.

Materials and Methods: This research is observational using a descriptive research design through a pharmacoeconomic analysis approach, namely Cost-Effectiveness Analysis. The data collection technique was retrospective by accessing data from medical records of outpatient hypertension patients who met the inclusion criteria. Data taken for cost-effectiveness analysis are data on antihypertensive effectiveness and direct medical costs.

Results: The combination of two antihypertensive drugs Calcium Channel Blocker (CCB) and Angiotensin II Receptor Blocker (ARB) with an ACER value of IDR 2,996 is the most cost-effective compared to the other combination groups.

Conclusion: The combination of two antihypertensive drugs Calcium Channel Blocker (CCB) and Angiotensin II Receptor Blocker (ARB) with an ACER value of IDR 2,996 is the most cost-effective compared to the other combination groups.